ClinicalTrials.gg
Status unknownNCT05500898Updated Aug 15, 2022

Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults

A Phase 1 interventional study of DWP16001 and DWC202204+DWC202205 in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-15.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
19 Years and older
Sex
Male
01

Study summary

The purpose of this study is to evaluate drug-drug interaction by comparing the pharmacokinetics (PK)/pharmacodynamics (PD), safety, and tolerability of single/multiple doses of DWP16001 , DWC202204 and DWC202205 alone or in combination in healthy male adults.

Read the detailed description

* Open label, multiple dose, 2 part, two period, single sequence design. This study is conducted on open label because it evaluates PK/PD parameters that are not affected by the blind. Volunteers who are suitable for the inclusion criteria are granted the final target number before the first dosage, receiving a fixed IP, and conducting a planned clinical trial schedule.

After having a rest period (7 days) in which the drug received is sufficiently metabolized and lost, the IP of the next period is administered.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male adults ≥ 19 years of age at the time of the screening procedure
  2. 18.5 ≤ (BMI) ≤ 27.0
  3. Voluntarily decided to participate in the study and provided written consent prior to the screening procedure after receiving a detailed explanation on this study and fully understanding the information
  4. Is eligible to participate in the study at the discretion of the investigator by a physical examination, laboratory test, and medical history questionnaire, etc.

Exclusion criteria

Exclusion Criteria:

  1. Presence or prior history of a hepatic, renal, nervous, respiratory, endocrine, hematologic and oncologic, cardiovascular, urogenital, psychiatric disorder
  2. Presence or prior history of a gastrointestinal disorder (e.g., gastrointestinal ulcers, gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease, etc.), or prior history of gastrointestinal surgery (except for simple appendectomy or hernia surgery) that may affect the safety and PK/PD assessment of the study drug.
  3. to, or history of clinically significant hypersensitivity to drugs including DWP16001 and other drugs of the same class (SGLT2 inhibitors), drugs including gemigliptin and other drugs of the same class, metformin and other drugs (aspirin, antibiotics, etc.)
  4. Considered ineligible for the study by the investigator for reasons including laboratory test results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    Experimental 1

    Drug: DWP16001

  • Experimental
    Experimental 2

    Drug: DWC202204+DWC202205

  • Experimental
    Experimental 3

    Drug: DWP16001+DWC202204+DWC202205

Interventions

  • Tablets, Oral, multiple doses of DWP16001

  • DrugDWC202204+DWC202205

    Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination

  • DrugDWP16001+DWC202204+DWC202205

    Drug page: Enavogliflozin

    Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination

06

What researchers measure

Primary outcomes

  1. Cmax,ss of DWP16001

    Peak Plasma Concetration at steady-state

    Time frame: [Time Frame: 0-72 hours]

  2. AUCtau,ss of DWP16001

    Area under the plasma concentration versus time curve at Tau, steady-state

    Time frame: [Time Frame: 0-72 hours]

  3. Cmax,ss of DWC202204 and DWC202205

    Peak Plasma Concetration at steady-state

    Time frame: [Time Frame: 0-24 hours]

  4. AUCtau,ss of DWC202204 and DWC202205

    Area under the plasma concentration versus time curve at Tau, steady-state

    Time frame: [Time Frame: 0-24 hours]

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2022; primary completion for Oct 2022, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2022
First posted
Aug 15, 2022
StartEst.
Aug 26, 2022
Primary completionEst.
Oct 31, 2022
CompletionEst.
Feb 28, 2023
Last update
Aug 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05500898
Responsible party
Sponsor
First posted
Aug 15, 2022
Start date
Aug 26, 2022 (estimated)
Primary completion
Oct 31, 2022 (estimated)
Completion
Feb 28, 2023 (estimated)
Last update
Aug 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion